{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Positive+Breast+Cancer&page=4",
    "query": {
      "condition": "HER2 Positive Breast Cancer",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 845,
    "total_pages": 85,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Positive+Breast+Cancer&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Positive+Breast+Cancer&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T02:05:19.513Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07427394",
      "title": "Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Camizestrant",
          "type": "DRUG"
        },
        {
          "name": "Atirmociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2026-05-06",
      "completion_date": "2027-12-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-04T02:05:19.513Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • East Providence, Rhode Island • Nashville, Tennessee",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "East Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07427394"
    },
    {
      "nct_id": "NCT07288359",
      "title": "Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced HR+/HER2- Breast Cancer",
        "Advanced CCNE1-amplified Solid Tumors",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GVV858",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2025-12-29",
      "completion_date": "2031-05-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-04T02:05:19.513Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Nashville, Tennessee • San Antonio, Texas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07288359"
    },
    {
      "nct_id": "NCT02515110",
      "title": "Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Node-positive Breast Cancer",
        "Breast Adenocarcinoma",
        "Invasive Breast Carcinoma",
        "Lobular Breast Carcinoma In Situ"
      ],
      "interventions": [
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "40 Years and older · Female only"
      },
      "enrollment_count": 137,
      "start_date": "2015-08-04",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-04T02:05:19.513Z",
      "location_count": 2,
      "location_summary": "Richmond, Virginia • South Hill, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        },
        {
          "city": "South Hill",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02515110"
    },
    {
      "nct_id": "NCT02040857",
      "title": "Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Aromatase Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 162,
      "start_date": "2014-01",
      "completion_date": "2024-12-27",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-04T02:05:19.513Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02040857"
    },
    {
      "nct_id": "NCT03280563",
      "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Entinostat",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 144,
      "start_date": "2017-12-22",
      "completion_date": "2024-09-26",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-04T02:05:19.513Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "West Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03280563"
    },
    {
      "nct_id": "NCT04752332",
      "title": "A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Standard Adjuvant ET",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2021-05-10",
      "completion_date": "2024-06-26",
      "has_results": true,
      "last_update_posted_date": "2025-07-15",
      "last_synced_at": "2026-10-04T02:05:19.513Z",
      "location_count": 13,
      "location_summary": "Glendale, Arizona • Los Angeles, California • Hollywood, Florida + 7 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04752332"
    },
    {
      "nct_id": "NCT00770809",
      "title": "Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Male Breast Carcinoma",
        "Stage IIA Breast Cancer AJCC v6 and v7",
        "Stage IIB Breast Cancer AJCC v6 and v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lapatinib Ditosylate",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 305,
      "start_date": "2009-02-24",
      "completion_date": "2024-02-15",
      "has_results": true,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-04T02:05:19.513Z",
      "location_count": 317,
      "location_summary": "Tucson, Arizona • Fort Smith, Arkansas • Burbank, California + 222 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Castro Valley",
          "state": "California"
        },
        {
          "city": "Castro Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00770809"
    },
    {
      "nct_id": "NCT03366844",
      "title": "Breast Cancer Study of Preoperative Pembrolizumab + Radiation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "RT Boost",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Stephen Shiao",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 66,
      "start_date": "2017-12-22",
      "completion_date": "2030-12-07",
      "has_results": true,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-10-04T02:05:19.513Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03366844"
    },
    {
      "nct_id": "NCT03584009",
      "title": "A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 103,
      "start_date": "2018-09-06",
      "completion_date": "2021-05-06",
      "has_results": true,
      "last_update_posted_date": "2022-06-28",
      "last_synced_at": "2026-10-04T02:05:19.513Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03584009"
    },
    {
      "nct_id": "NCT01850628",
      "title": "NSABP Biospecimen Discovery Project",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pertuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "NSABP Foundation Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2013-07",
      "completion_date": "2022-02",
      "has_results": false,
      "last_update_posted_date": "2021-10-05",
      "last_synced_at": "2026-10-04T02:05:19.513Z",
      "location_count": 5,
      "location_summary": "Gainesville, Florida • St Louis, Missouri • New York, New York + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01850628"
    }
  ]
}